Clinical Trial Update: Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of twice-daily oral iptacopan (LNP023) in adult Paroxysmal Nocturnal Hemoglobinuria patients with residual an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• iptacopan (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Status: COMPLETED | Results posted: 2023-11-28